A UCLA Health review of 565 studies on six popular unapproved peptides concluded that marketing claims about peptides are far ahead of the science.
The study concludes that the “critical gaps” in oversight pose significant patient safety risks, especially in sterile drug production.
Between February and July, the media covered pill press seizures in 13 states and customs forfeiture records reported seizures of 16 pill presses, six capsule-filling machines, and over 300 pill press parts, dies, and molds. Learn more about the last six months in pill press news.
May and June 2026 saw thousands of shipments of drugs imported into the US, including weight loss drugs and antibiotics. We studied these shipments to learn more about their manufacturers and contents.
Black market users lost an average of 4.7%, 5.3%, and 7.2% of their weight after taking “reta” for three months, six months, and one year, respectively. Those in clinical trials lost an average of 5.7%, 11.9%, and 15.5% over the same time intervals.
The unapproved retatrutide market holds immense safety risks, and patient safety and consumer groups are urging regulators, law enforcement, and the healthcare community to act decisively to protect Americans.
The U.S. Court of Appeals for the Fourth Circuit upheld the preliminary injunction filed against alternative funding programs and related vendors, in a major win for Gilead Sciences’ civil case.
35-year-old Tyreek Lewis just wanted his back pain to stop, but pain relief would mean time off from work, hours of tests, and extra appointments. So he took what looked like a simple shortcut. It killed him, and altered his family’s life forever.
Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement on the six lawsuits Eli Lilly filed today against businesses it accuses of illegally distributing unapproved copies of its investigational drug, retatrutide. Lilly is suing these defendants for illegal distribution of retatrutide including, in one case, a licensed 503A compounding pharmacy.
The appeals court’s decision in Gilead Sciences v. Meritain Health is unambiguous: you cannot import untraceable medicine with foreign-language labels, hand it to American patients, and call it equivalent to an FDA-approved medicine. Track-and-trace is a cornerstone of why the U.S. drug supply chain is the safest in the world, and it is not optional.